Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05662202 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

A Phase 3 study of Actinic Keratoses, sponsored by Biofrontera.

Active
Registry status
Phase 3
Development phase
172
Enrollment target
14
Study locations

NCT05662202: Active Phase 3 study of Actinic Keratoses, sponsored by Biofrontera.

NCT05662202 is a Phase 3 study of Actinic Keratoses that is active but no longer recruiting, run by Biofrontera. The registered enrollment target is 172 participants, above the 84-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (105% higher). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05662202, a Phase 3 study of Actinic Keratoses, is active but no longer recruiting, sponsored by Biofrontera.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
172 participants
Enrollment target
14
Study locations

Study Summary

The aim of this study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment for actinic keratosis (AK) on the extremities and neck/trunk.

Primary Outcome

Percentage of subjects with all AK target lesions clinically cleared after last PDT

Conditions Studied

Interventions

  • COMBINATION_PRODUCT BF-200 ALA and red light LED lamp
  • COMBINATION_PRODUCT Vehicle and red light LED lamp

Study Locations (14)

Texas

  • DermResearch, P.A. - Austin
  • Austin Institute for Clinical Research - Houston
  • Austin Institute for Clinical Research Inc. - Pflugerville

Arizona

  • Medical Dermatology Specialists - Phoenix
  • Alliance Dermatology & Mohs Center - Phoenix

Indiana

  • Laser and Skin Surgery Center of Indiana - Indianapolis
  • The Indiana Clinical Trials Center, PC - Plainfield

New York

  • Skin Search of Rochester, Inc. - Rochester
  • Rochester Dermatologic Surgery - Victor

Colorado

  • Dermatology Practice - Greenwood Village

Florida

  • Dermatology Associates PA of the Palm Beaches - Delray Beach

Georgia

  • Gwinnett Clinical Research Center, Inc. - Snellville

Louisiana

  • DelRicht Research - Baton Rouge

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2022-12-12
Est. Completion 2026-06
Phase Phase 3
Biofrontera

3 total trials

What the registry record for NCT05662202 still lists

NCT05662202 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, above the 84-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (105% higher).

The record links to 1 condition, with Actinic Keratoses appearing as the primary indexed condition, and to 2 interventions - of which BF-200 ALA and red light LED lamp is the first listed.

NCT05662202 lists 14 locations in 9 states (Texas, Arizona, Indiana).

Frequently Asked Questions

What is clinical trial NCT05662202 about?

NCT05662202 is a clinical study titled "Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp". The aim of this study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment for actinic keratosis ...

What is the current status of trial NCT05662202?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2022-12-12. Estimated completion is 2026-06.

What conditions does trial NCT05662202 study?

This clinical trial studies the following conditions: Actinic Keratoses.

What interventions are being tested in trial NCT05662202?

The interventions under investigation include: BF-200 ALA and red light LED lamp (COMBINATION_PRODUCT), Vehicle and red light LED lamp (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05662202?

This trial is sponsored by Biofrontera, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05662202 being conducted?

This trial has 14 study locations across Arizona, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Actinic Keratoses

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05662202's enrollment target sits among peer trials

172 2nd of 12 the highest of 12 other Actinic Keratoses trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Actinic Keratoses trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04801797 · 172 participants · Phase 2

    Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

  • NCT04867317 · 172 participants · Phase 3

    Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

  • NCT05357040 · 172 participants · Phase 2

    Antidepressant Effects of Nitrous Oxide

  • NCT05587517 · 172 participants · Phase 2

    A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05662202, the US trial registry maintained by the National Library of Medicine. NCT05662202 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.